BEI
ABBV icon

Benjamin Edwards Inc’s AbbVie ABBV Stock Holding History

Benjamin Edwards Inc’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.7M Sell
338,904
-1,639
-0.5% -$364K 0.73% 22
2025
Q4 		$77.8M Sell
340,543
-45,929
-12% -$10.5M 0.86% 14
2025
Q3 		$89.5M Buy
386,472
+12,094
+3% +$2.46M 1.01% 12
2025
Q2 		$69.5M Buy
374,378
+8,191
+2% +$1.52M 0.88% 18
2025
Q1 		$76.7M Buy
366,187
+14,089
+4% +$2.74M 1.07% 10
2024
Q4 		$62.6M Buy
352,098
+16,132
+5% +$2.97M 0.9% 16
2024
Q3 		$66.4M Buy
335,966
+298,322
+792% +$55.7M 0.97% 12
2024
Q2 		$6.46M Sell
37,644
-5,212
-12% -$863K 1.24% 10
2024
Q1 		$7.8M Buy
42,856
+2,851
+7% +$491K 1.55% 6
2023
Q4 		$6.2M Buy
40,005
+4,376
+12% +$638K 1.35% 6
2023
Q3 		$5.31M Buy
35,629
+145
+0.4% +$21.3K 1.26% 6
2023
Q2 		$4.78M Buy
35,484
+4,311
+14% +$632K 1.11% 16
2023
Q1 		$4.97M Buy
31,173
+3,638
+13% +$556K 1.21% 14
2022
Q4 		$4.45M Buy
27,535
+694
+3% +$106K 1.17% 12
2022
Q3 		$3.6M Buy
26,841
+471
+2% +$67.6K 1.08% 12
2022
Q2 		$4.04M Sell
26,370
-144
-0.5% -$22K 1.19% 8
2022
Q1 		$4.3M Buy
26,514
+10,961
+70% +$1.59M 1.25% 9
2021
Q4 		$2.11M Buy
15,553
+14,157
+1,014% +$1.67M 0.68% 36
2021
Q3 		$151K Buy
1,396
+693
+99% +$79.2K 0.09% 198
2021
Q2 		$79K Buy
703
+18
+3% +$2.03K 0.05% 240
2021
Q1 		$74K Buy
685
+62
+10% +$6.63K 0.06% 230
2020
Q4 		$67K Sell
623
-49
-7% -$4.71K 0.05% 223
2020
Q3 		$59K Buy
672
+6
+0.9% +$565 0.05% 204
2020
Q2 		$65K Sell
666
-66
-9% -$5.81K 0.05% 185
2020
Q1 		$56K Buy
732
+188
+35% +$16K 0.06% 164
2019
Q4 		$48K Buy
544
+144
+36% +$12K 0.1% 132
2019
Q3 		$30K Hold
400
– – 0.07% 143
2019
Q2 		$29K Hold
400
– – 0.07% 143
2019
Q1 		$32K Buy
+400
New +$32.7K 0.15% 136

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Benjamin Edwards Inc's ABBV Position: Q1 2026 in Review

Benjamin Edwards Inc reduced its AbbVie (ABBV) stake by 0.48% in Q1 2026, selling an estimated $364K and leaving 338,904 shares worth $73.7M. The position accounts for 0.73% of the portfolio, ranked #22.

Benjamin Edwards Inc first reported a position in ABBV in Q1 2019 and has held it in 29 quarters since. The position peaked at $89.5M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Benjamin Edwards Inc held 338,904 shares of AbbVie worth $73.7M as of Q1 2026.
  • Benjamin Edwards Inc sold 1,639 AbbVie shares in Q1 2026, an estimated $364K.
  • AbbVie made up 0.73% of Benjamin Edwards Inc's portfolio in Q1 2026, its #22 holding.
  • Benjamin Edwards Inc first reported a position in AbbVie in Q1 2019 and has held it in 29 quarters since.
  • Benjamin Edwards Inc's AbbVie position peaked at $89.5M in Q3 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Benjamin Edwards Inc's 13F filing for Q1 2026, filed 12 May 2026.